

# BMJ Open A randomised controlled trial of fluoxetine versus naltrexone in compulsive sexual behaviour disorder: presentation of the study protocol

Josephine Savard <sup>1,2</sup>, Katarina Görts Öberg,<sup>2,3</sup> Cecilia Dhejne,<sup>2,3</sup> Jussi Jokinen<sup>1,4</sup>

**To cite:** Savard J, Görts Öberg K, Dhejne C, *et al.* A randomised controlled trial of fluoxetine versus naltrexone in compulsive sexual behaviour disorder: presentation of the study protocol. *BMJ Open* 2022;**12**:e051756. doi:10.1136/bmjopen-2021-051756

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-051756>).

Received 27 March 2021  
Accepted 19 May 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

<sup>1</sup>Department of Clinical Sciences/Psychiatry, Umeå University, Umeå, Sweden

<sup>2</sup>ANOVA clinic, Karolinska University Hospital, Stockholm, Sweden

<sup>3</sup>Department of Medicine, Karolinska Institutet, Stockholm, Sweden

<sup>4</sup>Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

## Correspondence to

Josephine Savard;  
[josephine.savard@umu.se](mailto:josephine.savard@umu.se)

## ABSTRACT

**Background** Compulsive sexual behaviour disorder is a new disorder in the International Classification of Diseases (ICD-11), and is associated with negative consequences in different areas of life. Evidence for pharmacological treatment of compulsive sexual behaviour disorder is weak and treatment options are limited. This proposed study will be the largest and the first randomised controlled trial comparing the efficacy and tolerability of two active drugs in compulsive sexual behaviour disorder.

**Methods and analysis** Eighty adult participants with compulsive sexual behaviour disorder according to ICD-11 will be randomised to receive either naltrexone 25–50 mg or fluoxetine 20–40 mg for 8 weeks, followed by 6 weeks without treatment. The study will be conducted in a subspecialised outpatient sexual medicine unit at Karolinska University Hospital, Stockholm, Sweden. The study is financed by grants and entirely independent of the manufacturers.

Exclusion criteria include severe psychiatric or psychical illness, changes to concurrent medication and non-compatible factors contraindicating the use of either drug. The primary outcome measure is the Hypersexual Disorder: Current Assessment Scale (HD: CAS), and tolerability will be assessed by the Udvalg for Kliniske Undersogelser side effect rating scale (UKU), drug accountability, adherence to treatment and drop-out rate. Participants will complete questionnaires at regular intervals, with the main endpoint for efficacy after 8 weeks (end of treatment) and after 14 weeks (follow-up). Blood chemistry will be repeatedly collected as a safety precaution and for research purposes. The results will be analysed using an appropriate analysis of variance model or a mixed model, depending on the distribution of HD: CAS and the extent of missing data.

**Ethics and dissemination** The Swedish Ethical Review Authority and the Swedish Medical Products Agency have approved the study on 27 May 2020 and 4 June 2020, respectively (ref. no. 2020-02069 and ref. no. 5.1-2020-48282). Findings will be published in peer-reviewed journals and presented at relevant conferences.

**Trial registration number** 2019-004255-36

## INTRODUCTION

Compulsive sexual behaviour disorder (CSBD) is a newly defined diagnosis in the

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This is the first randomised controlled trial comparing the efficacy of two pharmacological agents in compulsive sexual behaviour disorder—naltrexone and fluoxetine.
- ⇒ The study enables assessment of clinical, psychosocial and biological predictors of treatment response.
- ⇒ The lack of placebo-control is a limitation.
- ⇒ The study protocol duration of 14 weeks may be seen as limitation of the study design.

impulse control disorder section of the 11th edition of the International Classification of Diseases (ICD-11).<sup>1</sup> It entails a persistent pattern of failure to control intense repetitive sexual impulses or urges, resulting in sexual behaviours with negative consequences affecting different areas of life. Adverse consequences associated with CSBD include distress, unwanted pregnancies, sexually transmitted diseases, relationship problems, financial expenses, occupational impairment and risk of crime. Considering these potential severe consequences and the suggested prevalence of 3%–6% of the population,<sup>2</sup> there is an undisputable, urgent need for effective treatments.

Existing drug studies of CSBD have mainly been case reports and small open-label studies on selective serotonin reuptake inhibitors (SSRIs),<sup>3 4</sup> antiandrogens<sup>4</sup> or the opioid antagonist naltrexone.<sup>5–8</sup> Only one randomised controlled trial has examined the effect of an SSRI (citalopram 20–60 mg/day for 12 weeks) in 28 gay and bisexual men with non-paraphilic compulsive sexual behaviour.<sup>9</sup> There was no significant difference in the main outcome measure Yale-Brown Obsessive Compulsive Scale-Compulsive Sexual Behavior (Y-BOCS-CSB) score between those assigned citalopram and those assigned placebo.



CSBD and paraphilic disorders are regarded as separate conditions, however, a high level of sexual preoccupation is common in both.<sup>10–13</sup> To aid physicians in clinical practice, the World Federation of Societies of Biological Psychiatry (WFSBP) has provided treatment guidelines for paraphilic disorders.<sup>14,15</sup> Psychotherapy is proposed as a first step for low-risk individuals. If results are unsatisfactory, the next step includes SSRIs.

The subsequent levels in the guidelines are for individuals with moderate-high risk for sexual violence and include testosterone-lowering agents such as cyproterone acetate and gonadotropin-releasing hormone agonists. These agents decrease the frequency and intensity of sexual desire and arousal, however use is associated with high rates of adverse effects. Hormonal treatment is potentially unsuitable for help-seeking individuals with conventional CSBD. In order to investigate appropriate pharmacological alternatives, the proposed 14-week randomised controlled trial will compare the efficacy of two active drugs in 80 adults with CSBD. Additional aims are to examine tolerability and what clinical characteristics and biomarkers could be predictors of response.

Based on the WFSBP treatment guidelines and available research,<sup>9</sup> the SSRI *fluoxetine* will be defined as standard treatment. Alternative treatment will consist of *naltrexone*, an opioid antagonist which prevents reinforcing effects in the mesolimbic reward centre and is used in the treatment of alcohol use disorder.<sup>16</sup> Naltrexone was chosen due to similarities between CSBD and other urge-driven disorders, and promising results in CSBD case reports, and in our pilot study of 20 men conducted during 2018–2019.<sup>17</sup> In the latter, all participants completed the 8-week study protocol, and no serious adverse events occurred. Although adverse reactions were common, all were considered mild to moderate, and most were transient during the first days-week. Hence, we were able to determine that naltrexone was a well-tolerated, feasible treatment option and gave indications of symptom relief. However, as the study format prohibited conclusion of efficacy, this study aims to further investigate naltrexone in the treatment of CSBD.

### Primary objective

To compare the effect of naltrexone versus fluoxetine in CSBD.

### Secondary objectives

To investigate if clinical, psychosocial or biological factors can predict treatment response.

To compare if there are any differences in drop-out rate and adherence between the two treatment groups.

To assess side effects and investigate any connection between drop-out rate, reports of side effects and/or efficacy.

To compare if there is a difference in the participants' wish to resume treatment.

To investigate biological markers and clinical parameters in participants with CSBD.

To investigate correlation between CSBD and impulsiveness, experience of violence and suicidality.

## METHODS AND ANALYSIS

### Study setting and study design

The study will be conducted at ANOVA, a subspecialised sexual medicine outpatient clinic at Karolinska University Hospital in Stockholm, Sweden. Eligible participants will be randomised in blocks with a 1:1 allocation to receive either fluoxetine or naltrexone in a superiority parallel group design for 8 weeks followed by a 6-week follow-up phase. Blinding will not be applicable due to the different appearances of the drugs and dose augmentation in different time intervals due to different pharmacological properties.

### Protocol version

Version identifier: 2.0. Number of protocol amendments: 1; 25 June 2020; main changes included adding blood samples and assessments for safety reasons as requested by the Swedish Medical Products Agency.

### Eligibility criteria

Please see [box 1](#) for inclusion and exclusion criteria.

### Recruitment, randomisation and allocation

The study will be advertised in media and an initial screening regarding compulsive sexual behaviour, and inclusion and exclusion criteria ([box 1](#)) will be conducted when potential candidates call the national helpline PrevenTell for individuals with self-identified compulsive sexual behaviour and/or paraphilia. Persons likely to meet criteria for CSBD will receive information about the study and be invited to log into a secure web-based platform to leave a preliminary informed consent and fill in questionnaires.

Participants will thereafter attend a baseline visit at the clinic. After obtaining written informed consent (online supplemental file 1), urine samples will be collected and screened for recreational drug use (eg, amphetamine, benzodiazepines, cannabis, cocaine and opioid) and blood samples will be collected (eg, monitoring of testosterone, luteinizing hormone, glucose, electrolytes and liver enzymes) ([table 1](#)). Specific research samples will also be collected (eg, DNA extraction for genome-wide methylation analysis (EPIC) and second-generation DNA sequencing).

A psychiatrist will obtain a medical and psychiatric history, perform a physical examination including blood pressure and heart and pulmonary auscultation, as well as perform interviews with the Mini International Neuropsychiatric Interview (MINI)<sup>18</sup> and Columbia Suicide Severity Rating Scale (C-SSRS).<sup>19</sup> The study psychologist will focus on sexual behaviours by conducting a structured interview addressing the ICD-11 criteria for CSBD and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for hypersexual disorder as originally proposed for inclusion<sup>20</sup> and paraphilia(s). The separate psychiatrist and psychologist interviews aim

**Box 1 Inclusion and exclusion criteria**
**Inclusion criteria**

- ⇒ Meet criteria for compulsive sexual behaviour disorder according to ICD-11 and fulfil criteria for hypersexual disorder as originally proposed for inclusion in DSM-5.
- ⇒ Between 18 and 65 years.
- ⇒ Understand oral and written Swedish and have internet access.
- ⇒ Willing to participate in all study visits including providing blood and urine samples.
- ⇒ Signed informed consent form.
- ⇒ For fertile women: the use of a safe method of contraception during the entire study protocol.

**Exclusion criteria**

- ⇒ Signs of hepatitis, elevated liver enzymes (>3 times over reference) or a history of liver failure.
- ⇒ eGFR <60 mL/min, signs or history of acute kidney failure.
- ⇒ fp-glucose ≥7.0 mmol/L.
- ⇒ Known heart disease such as angina pectoris, previous heart failure or heart attack.
- ⇒ Other serious physical illness including diabetes mellitus, epilepsy or known ocular hypertension.
- ⇒ Treatment in the past month (≥1 dose) with opioids or benzodiazepines.
- ⇒ Treatment in the past month with oral anticoagulants such as warfarin. Intermittent treatment (max. 15 doses per week) with NSAID (eg, ibuprofen) is tolerated.
- ⇒ Treatment with tamoxifen.
- ⇒ Self-reported use of recreational drugs in the past month or positive drug verification analysis.
- ⇒ Alcohol dependence or risk consumption (>14 units of alcohol per week for men, >9 for women) in the past month.
- ⇒ Severe psychiatric disorder requiring immediate treatment such as current psychotic disorder or severe depression.
- ⇒ Bipolar disorder or history of hypomania.
- ⇒ Ongoing treatment with naltrexone or SSRI, or previous hypersensitivity reaction to either.
- ⇒ Change of concurrent medication or dosage in the past 3 months regarding antidepressants, ADHD medication, mood stabilisers, antipsychotics, cortisone, testosterone or dopamine precursors. Smaller adjustments may in some cases be acceptable (assessed by study psychiatrist).
- ⇒ Ongoing pharmacological treatment with contraindicated substances (eg, tamoxifen and metoprolol).
- ⇒ Pregnancy and/or breastfeeding.
- ⇒ Mental condition that could negatively influence either the participant's health or the scientific aspects of the study. High risk for committing sexual offence is included.
- ⇒ Ongoing psychotherapeutic treatment.
- ⇒ Participation in other studies outside ANOVA.

ADHD, attention-deficit/hyperactivity disorder; DSM-5, diagnostic and statistical manual of mental disorders, fifth edition; eGFR, estimated glomerular filtration rate; NSAID, non-steroidal anti-inflammatory agents; SSRIs, selective serotonin reuptake inhibitors.

to determine eligibility criteria in an unbiased manner. If unmatched opinions, the participant will not be included.

The research nurse will open envelopes for randomisation and supply enrolled participants with either naltrexone or fluoxetine accordingly. The allocation

**Table 1** Samples analysed during the study

Screening		
S-FSH	P-ASAT	P-Sodium
S-LH	P-Calcium	
S-SHBG	fP-Glucose	Full blood cell count
S-Testosterone	P-GT	B-HbA1c
S-TSH	P-HDL Cholesterol	
S-T4	P-Potassium	U-screening for substance abuse*
P-Albumin	P-Cholesterol	U-Pregnancy test†
P-ALAT	P-Creatinine	
P-ALP	fP-LDL Cholesterol	Research samples‡
At 4 weeks		
P-ALAT	P-GT	Full blood cell count
P-ALP	P-Potassium	
P-ASAT	P-Creatinine	U-Pregnancy test†
P-Glucose	P-Sodium	
At 8 weeks		
P-ALAT	P-Creatinine	U-Pregnancy test†
P-ALP	P-Sodium	P-Fluoxetine or U-Naltrexone§
P-ASAT	Full blood cell count	
P-GT	B-HbA1c	Research samples‡
P-Potassium		

\*Amphetamine, benzodiazepines, buprenorphine, cannabis, cocaine, fentanyl, methadone, oxycodone, tramadol and other opioids.

†Assigned female at birth only.

‡E.g. DNA extraction for genome-wide methylation analysis (EPIC) and second-generation DNA sequencing, oxytocin pretreatment and post-treatment.

§Depending on randomisation.


sequence is created by an independent investigator at the Karolinska Trial Alliance, a research centre that supports clinical trials. Participants will start treatment if results on blood chemistry are adequate.

The study drugs will be provided by the Karolinska University Hospital's pharmacy.

Naltrexone (AOP Orphan Pharmaceuticals): initial dose 25 mg per day, and if tolerated will be augmented to 50 mg per day after 3–5 days.

Fluoxetine (Orion Pharma): Initial dose 20 mg per day, and if unsatisfactory symptom reduction and tolerated will be augmented to 40 mg per day after 4 weeks.

In Sweden, The Dental and Pharmaceutical Benefits Agency, a central government agency determines what pharmaceutical product shall be subsidised by the state. The agency also recommends manufacturers for specific drugs based on for example, price and availability. The manufacturers for naltrexone and fluoxetine in this study were chosen as they were the agency's recommended product when the application was prepared for submission.



**Figure 1** Flowchart. \*If unsatisfactory symptom reduction and tolerated.

### Intervention

Figure 1 illustrates study procedures. Participants will assess their symptoms weekly by filling in questionnaires online for example, if they have noticed any change in frequency or intensity of sexual urges or behaviours, how they perceive the treatment and if they experience adverse reactions. Every second week, participants will complete the main outcome measure Hypersexual Disorder: Current Assessment Scale (HD: CAS).<sup>21</sup> After 4 weeks, new blood samples will be collected, and participants will have a telephone consultation with the study psychiatrist to assess tolerability and psychiatric well-being. Fertile women will be required to conduct a pregnancy test before starting the study and use contraception during the study period. At end of treatment, participants will have a consultation with the study psychiatrist to assess current symptoms of CSBD, psychiatric distress and tolerability. Blood samples will be collected for chemical analysis as well as monitoring drug tablet return and the metabolites of naltrexone respective fluoxetine.

Six weeks after the end of treatment, the participants will fill in questionnaires and have a final consultation with the study psychiatrist. The visits at the clinic and the drugs will be free of charge.

### Outcome measures

The main outcome is symptom relief as assessed with HD: CAS, which measures symptom severity during the previous 2 weeks according to the suggested conceptualisation of Hypersexual Disorder to the DSM-5.<sup>20</sup> Corresponding scales for the ICD-11 diagnosis have not yet been developed. We chose a scale that is sensitive to changes and participants will be asked to fill it in at baseline, every second week during the treatment phase and at end of study. However, as the scale is not validated, two additional measures will be used: the Hypersexual Behaviour Inventory (HBI)<sup>22</sup> and the Sexual Compulsivity Scale (SCS).<sup>23</sup> Using unpublished data from our research centre, the correlations (Pearson's) between HD: CAS and HBI were positive at baseline and post-treatment.

We will also analyse factors (clinical, psychosocial or biological) that may be predictors of response, and whether there is any difference in participants' readiness to resume pharmacological treatment at end of study.

Furthermore, we will also evaluate tolerability using the Udvalg for Kliniske Undersogelser side effect rating scale (UKU),<sup>24</sup> drug accountability, adherence to treatment, and drop-out rate.

Finally, to aid in understanding CSBD, we will assess for impulsivity, suicidality and childhood adversities, and

**Table 2** Study assessments

Objective	Assessments	Measure type	Time point
Assess changes in compulsive sexual behaviours from screening to week 8 and follow-up	Hypersexual Disorder: Current Assessment Scale (HD: CAS)	Outcome	Baseline, weeks 2, 4, 6, 8 and end of study
Assess compulsive sexual behaviours	The Hypersexual Disorder Screening Inventory (HDSI)	Eligibility	Baseline, and end of study
Assess changes in compulsive sexual behaviours from screening to week 8 and follow-up	The Hypersexual Behaviour Inventory (HBI)	Outcome	Baseline, weeks 1–4, week 6, week 8 and end of study
Assess changes in compulsive sexual behaviours from screening to week 8 and follow-up	Sexual Compulsivity Scale (SCS)	Outcome	Baseline, weeks 1–4, week 6, week 8 and end of study
Assess sexual interests	Self-assessment of sexual interests (SSI)	Eligibility	Baseline
Assess sexual dysfunction	International Index of Erectile Function (IIEF)*	Eligibility	Baseline
Assess psychiatric comorbidity	Mini-International Neuropsychiatric Interview (MINI)	Eligibility	Baseline
Assess changes in depression severity from screening to week 8 and follow-up	Montgomery Åsberg Depression Rating Scale—self-rating (MADRS-S)	Outcome safety	Baseline, week 8 and end of study
Assess change of symptoms of depression and anxiety from screening to week 8 and follow-up	Hospital Anxiety and Depression Scale (HAD)	Outcome	Baseline, week 8 and end of study
Assess changes in alcohol use from screening to week 8 and follow-up	Alcohol Use Disorders Identification Test (AUDIT)	Outcome	Baseline, week 8 and end of study
Assess use of drugs	Drug Use Disorders Identification Test (DUDIT)	Eligibility	Baseline
Assess pathological gambling	Gambling Disorder Identification Test (G-DIT)	Eligibility	Baseline
Assess impulsivity	Barratt Impulsiveness Scale (BIS-11)	Eligibility	Baseline
Assess symptoms of attention-deficit/hyperactivity disorder	Adult ADHD Self-Report Scale (ASRS)	Eligibility	Baseline
Assess history of violence	Karolinska Interpersonal Violence Scale (KIVS)	Eligibility	Baseline
Assess history of childhood trauma	The Childhood Trauma Questionnaire—Short Form (CTQ-SF)	Eligibility	Baseline
Assess suicide ideation and suicidal behaviour throughout the study	Columbia Suicide Severity Rating Scale (C-SSRS)	Safety	Baseline, weeks 1, 4, 8 and end of study
Assess adverse reactions in week 8	Udvalg for Kliniske Undersogelser side effect rating scale (UKU)	Tolerability	Week 8
Question of wanting to resume pharmacological treatment, week 14	Yes/no/do not know option	Outcome	End of study

\*Assigned men at birth only.

collect biological markers (eg, DNA and hormones) to evaluate their potential association with CSBD. A summary of assessments and biological markers is presented in [tables 1 and 2](#), and supplemental table (online supplemental file 2). Furthermore, an extension of the study is planned to include neuroimaging data collection.

### Adherence and concomitant care

Participants can leave the study at any time without giving a reason, however any material already obtained will be analysed. Participants who miss  $\geq 3$  doses in a row will be

considered as having ceased treatment. Other reasons for discontinuation of treatment include severe adverse reactions, severe psychiatric condition where the safety of the participant or others cannot be guaranteed, initiation of treatment with non-compatible drugs or use of recreational drugs, pregnancy or start of psychotherapy.

### Sample size and statistical methods

Since there is no gold standard for the measurement of pharmacological treatment outcomes in CSBD, the sample size calculation is based on HD: CAS from a

study of Cognitive Behavioural Therapy from our clinic<sup>25</sup> (using expanded data available postpublication, n=76). The difference in HD: CAS prepost treatment was 4.065 with a SD of 4.74. A statistical power of 80%, an error probability of 0.05 and a difference between the groups of 3.3 (meaning an effect size of 0.7) would render a sample size of 34 participants in each group. To adjust for potential dropouts, we aim to include 80 participants. The results will be analysed using an appropriate analysis of variance model or a mixed model, depending on the distribution of HD: CAS and the extent of missing data. Participants who discontinue treatment will be included in an intention-to-treat analysis. Per-protocol analysis will also be used. To increase the study's credibility, the extent and nature of missing data will be reported for each treatment group, as well as any predictors of missing data (eg, young age).

### Monitoring

As required, an independent trial investigator from the Karolinska Trial Alliance will regularly control and quality assure the study procedures. There will be no interim analysis.

### Patient and public involvement

Patients and the public will not be involved in the design of the study other than the input from the participants and outcomes from the pilot study.<sup>17</sup>

### Ethics and dissemination

The study procedures will be carried out in accordance with the Declaration of Helsinki and European Good Clinical Practice Guidelines. The Swedish Ethical Review Authority and the Swedish Medical Products Agency have approved the study (ref. no. 2020-02069 and ref. no. 5.1-2020-48282). The registration of the trial is accessible at <https://www.clinicaltrialsregister.eu>. Study enrollment started in October 2020.

Eligible participants will be aged  $\geq 18$  years and understand both oral and written Swedish. Paraphilic interests are not an exclusion criterion, whereas severe risk for sexual violence (as reported in the interviews and questionnaires, eg, participants who report that they actively interact with children for sexual purposes) is.

The study psychiatrists and psychologists are experienced in evaluating and treating patients with CSBD and paraphilic disorders, and the investigators will together decide whether the individual may be a potential study candidate.

The risks for the participants including safety aspects of the drugs have been carefully weighed against the potential benefits of conducting the study, and we believe the latter outweighs the former. The participants' health and safety will be assessed and prioritised, which may entail discontinuation of treatment. All undesirable medical events that come to our attention will be graded (mild if the symptoms are transient, moderate if temporary medical treatment for relief is needed and

severe if hospital care or prolonged medical treatment is needed) and followed until the event is resolved. Serious adverse events and suspected unexpected serious adverse reactions are handled and reported as required by the Swedish Medical Products Agency. The same insurance regulation as in ordinary medical care apply.

Research data from the web-based platform will be stored securely in servers with restricted access. Archived paper material will be stored in a locked cabinet, in accordance with current legislation and regulations. Research samples and data will be destroyed 10 years after declaring end of trial to the Swedish Medical Products Agency.

Authorship eligibility will be assured in accordance with The International Committee of Medical Journal Editors (ICMJE) guidelines. The results of the study will be presented at scientific conferences and in peer-review articles. Once the trial has been published, participants will be informed about the study results on a group level and results suitable for a non-specialist audience will be accessible on our website.

### DISCUSSION

As presented in the introduction, there is currently weak evidence for the pharmacological treatment of CSBD (for review, see Grubbs *et al*<sup>26</sup>) and hence a clear need for randomised controlled trials. However, some aspects of this study design and concept need to be discussed.

#### Feasibility of enrollment

Participants might be unwilling to participate in a drug trial, hence it may be difficult to complete recruitment within the designated period of 3 years, leading to a sample too small for rendering power in the analyses. In addition, the COVID-19 pandemic might complicate participants' travel to our clinic or even our capacity to conduct the study due to restrictions in the provision of healthcare (eg, limited to emergency care only). An over-representation of participants living in the Stockholm area is to be expected.

#### Eligibility

We try to minimise the risk for recruiting a homogeneous group of persons with CSBD by inviting individuals with a broad range of severity of symptoms, and the use of randomisation with allocation concealment to minimise the risk for selection bias between the groups. Nevertheless, as with most studies, there is a risk for an over-representation of those with a better prognosis.

The exclusion criteria are more stringent than the inclusion criteria, partly due to the safety profiles of the drugs—a situation that regardless of study protocol would influence their use in a regular clinical setting. However, we also exclude participants with ongoing recreational drug use to minimise the risk of confounders. We also exclude participants currently being treated with interacting antidepressants and

those with a severe psychiatric disorder requiring immediate treatment, as these patients are too sick to follow our study protocol. Most patients seeking treatment at ANOVA for CSBD do not fall into these categories (particularly not the latter), but this exclusion criterion will undoubtedly lead to the inclusion of healthier individuals in the study. Although we aim to have a representative sample, a certain impact on the external validity is to be expected.

### Outcome ascertainment

As noted, our main outcome variable HD: CAS is not validated. However, it has a predefined timespan of symptom relief and has been used in previous studies at our research centre. When comparing results of HD: CAS with the validated HBI, the latter reaches a floor-effect post-treatment, whereas HD: CAS seems to better distinguish effects. Our overall judgement is thus that the advantages of the HD: CAS outweigh the disadvantages.

The HBI has an item addressing craving ‘My sexual cravings and desires feel stronger than my self-discipline’. Nevertheless, we are aware that using this single item to assess craving may be a limitation.

Another limitation is that this study will not be blinded, and we will not be able to control for the anticipation effect in either group. Nonetheless, group comparisons using regression models with incorporated baseline data will still be of major value and results will be of importance to guide clinical praxis and for future meta-analyses. Finally, the study protocol duration of only 14 weeks is a major limitation, but the length was chosen for feasibility reasons. Even so, if adherence to naltrexone will be low, future studies could consider using extended-release injectable naltrexone. Fluoxetine will presumably reach steady state between weeks 4 and 8, and with this aspect in mind, the comparisons between the groups after reaching steady state will be the most informative as well as being deemed sufficient to provide important clinical knowledge.

**Acknowledgements** The authors wish to thank Tania McConaghy for language revision.

**Contributors** JS, KGÖ, CD and JJ conceived and designed the study. JS and JJ contributed to the statistical plan. JJ is grant holder. JS drafted the manuscript, and all authors contributed substantially to refinement of the manuscript. All authors approved the final version.

**Funding** This work was supported by the Swedish Research Council grant number 2020-01183 and regional agreements between ANOVA, Region Stockholm and Region Västerbotten (ALF Region Västerbotten grant number RV-929554). The pharmaceutical companies are not providing funding or being involved in any other way.

**Competing interests** JJ has participated in Advisory Board of Janssen concerning esketamine for MDD with current suicidal ideation. The other authors report no conflicts of interest.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

### ORCID iD

Josephine Savard <http://orcid.org/0000-0002-0140-4109>

### REFERENCES

- World Health Organization. The 11th revision of the International classification of diseases (ICD-11). Available: <https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2fcd%2fentify%2f274880002> [Accessed 9 Feb 2020].
- Kuzma JM, Black DW, Epidemiology BDW. Epidemiology, prevalence, and natural history of compulsive sexual behavior. *Psychiatr Clin North Am* 2008;31:603–11.
- Gola M, Potenza MN. Paroxetine treatment of problematic pornography use: a case series. *J Behav Addict* 2016;5:529–32.
- Winder B, Lievesley R, Elliott H, et al. Evaluation of the use of pharmacological treatment with prisoners experiencing high levels of hypersexual disorder. *J Forens Psychiatry Psychol* 2018;29:53–71.
- Raymond NC, Grant JE, Kim SW, et al. Treatment of compulsive sexual behaviour with naltrexone and serotonin reuptake inhibitors: two case studies. *Int Clin Psychopharmacol* 2002;17:201–5.
- Ryback RS. Naltrexone in the treatment of adolescent sexual offenders. *J Clin Psychiatry* 2004;65:982–6.
- Raymond NC, Grant JE, Coleman E. Augmentation with naltrexone to treat compulsive sexual behavior: a case series. *Ann Clin Psychiatry* 2010;22:56–62.
- Bostwick JM, Bucci JA. Internet sex addiction treated with naltrexone. *Mayo Clin Proc* 2008;83:226–30.
- Wainberg ML, Muench F, Morgenstern J, et al. A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. *J Clin Psychiatry* 2006;67:1968–73.
- Kafka MP, Hennen J. The paraphilia-related disorders: an empirical investigation of nonparaphilic hypersexuality disorders in outpatient males. *J Sex Marital Ther* 1999;25:305–19.
- Sutton KS, Stratton N, Pytyck J, et al. Patient characteristics by type of hypersexuality referral: a quantitative chart review of 115 consecutive male cases. *J Sex Marital Ther* 2015;41:563–80.
- Kafka MP, Hennen J. Hypersexual desire in males: are males with paraphilias different from males with paraphilia-related disorders? *Sex Abuse* 2003;15:307–21.
- Engel J, Veit M, Sinke C, et al. Same Same but Different: A Clinical Characterization of Men with Hypersexual Disorder in the Sex@Brain Study. *J Clin Med* 2019;8. doi:10.3390/jcm8020157. [Epub ahead of print: 30 01 2019].
- Thibaut F, De La Barra F, Gordon H, et al. The world Federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. *World J Biol Psychiatry* 2010;11:604–55.
- Thibaut F, Cosyns P, Fedoroff JP, et al. The world Federation of societies of biological psychiatry (WFSBP) 2020 guidelines for the pharmacological treatment of paraphilic disorders. *World J Biol Psychiatry* 2020;21:412–90.
- Franck J, Jayaram-Lindström N. Pharmacotherapy for alcohol dependence: status of current treatments. *Curr Opin Neurobiol* 2013;23:692–9.
- Savard J, Öberg KG, Chatzittofis A, et al. Naltrexone in compulsive sexual behavior disorder: a feasibility study of twenty men. *J Sex Med* 2020;17:1544–52.
- Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International neuropsychiatric interview (M.I.N.I.): the development and



- validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* 1998;59 Suppl 20:22-33;quiz 34-57.
- 19 Posner K, Brown GK, Stanley B, *et al*. The Columbia-Suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. *Am J Psychiatry* 2011;168:1266-77.
- 20 Kafka MP. Hypersexual disorder: a proposed diagnosis for DSM-V. *Arch Sex Behav* 2010;39:377-400.
- 21 American Psychiatric Association. Hypersexual Disorder: current assessment scale. American Psychiatric Association's DSM-V workgroup on Sexual and Gender Identity Disorders, 2010. Available: <http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx?rid=415> [Accessed Mar 2010].
- 22 Reid RC, Garos S, Carpenter BN. Reliability, validity, and psychometric development of the Hypersexual behavior inventory in an outpatient sample of men. *Sex Addict Compulsivity* 2011;18:30-51.
- 23 Kalichman SC, Rompa D. Sexual sensation seeking and sexual Compulsivity scales: reliability, validity, and predicting HIV risk behavior. *J Pers Assess* 1995;65:586-601.
- 24 Lindström E, Lewander T, Malm U, *et al*. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. clinical validation of a self-rating version of the UKU side effect rating scale (UKU-SERS-Pat). *Nord J Psychiatry* 2001;55 Suppl 44:5-69.
- 25 Hallberg J, Kaldo V, Arver S, *et al*. Internet-Administered Cognitive Behavioral Therapy for Hypersexual Disorder, With or Without Paraphilia(s) or Paraphilic Disorder(s) in Men: A Pilot Study. *J Sex Med* 2020;17:2039-54.
- 26 Grubbs JB, Hoagland KC, Lee BN, *et al*. Sexual addiction 25 years on: A systematic and methodological review of empirical literature and an agenda for future research. *Clin Psychol Rev* 2020;82:101925.



## INFORMED CONSENT FORM

**Pharmacological treatment of Compulsive Sexual Behavior**

- a comparison of the effectiveness of naltrexon versus fluoxetine: the CeSar-study

**Background and aim**

Here at ANOVA clinic we treat persons who experience a troublesome or dangerous sexuality. There is a lack of knowledge regarding treatment of intrusive sexual thoughts, impulses and behaviors in individuals with compulsive sexuality, sometimes called “sexual addiction”. This study is evaluating a new drug for this purpose, naltrexone. Naltrexone is currently used in the treatment of alcohol dependence and has been reported as a drug that can also reduce both urges and behaviors linked to compulsive sexual behavior. To compare the new treatment, half of the participants will instead receive fluoxetine which is used for the treatment of compulsive sexuality nationally and internationally.

The overall purpose of this study is to improve the treatment options and the quality of life for the individual.

**Request for participation**

You have contacted or been referred to ANOVA and are therefore asked to participate. Participation is voluntary.

**How is the study conducted?**

If you are interested in participating in the study and provide an informed consent in the web platform, you will be asked to complete an online survey for approximately 60-90 minutes with questions on your sexuality and your general well-being. The online survey is the first step in the study and aims to provide increased knowledge about sexuality that leads to negative consequences.

After you have filled in the online survey, you will be contacted by mail or telephone and offered an appointment at the clinic ANOVA. You will meet a physician and psychologist for two interviews. They will evaluate if you meet the requirements to be enrolled in the study and you will have the opportunity to ask questions. If you want to proceed with the study, you will be requested to sign an informed consent for participation in the drug treatment. You will also be asked to participate in a computerized test of impulsivity and to submit a routine blood test to map sex hormones and liver-, thyroid- and kidney function and metabolic status (= 5 tubes, approximately 20ml) before treatment. We also ask for a urine sample to have objective measures to exclude a recreational drug use. This urine sample is discarded if it is negative or sent to a laboratory for further analysis if positive as done with routine sample in healthcare. If you are a woman of childbearing age, you will have to submit a sample (urine or blood sample, a 3.5ml tube) to rule out pregnancy and are encouraged to use a safe contraception method during the study.

We also ask if you are willing to provide research blood samples (max. 100ml) with the aim to examine neurobiological markers of compulsive sexuality. These samples include e.g. DNA extraction, see further under the heading Biobank below.

Estimated time required for the visits is about 3 hours.

If you are offered treatment within the framework of the study, you will receive treatment for 8 weeks with either naltrexone or fluoxetine. The selection is made through randomization (i.e. assignment by chance). You will know which of the preparations you have been randomized to, but will not have the opportunity to choose drug.

You will be contacted by phone after 3-5 days and after 4 weeks to inquire about mood and possibly adjust the dose. At 4 weeks, you will be asked to provide new blood samples (3 tubes, approx. 12 ml).

You will be asked to report any side effects and if you notice any changes since the start of medication in the web-based platform. In addition, you will be asked to fill questionnaires every week that assess your mood and your sexual problems. Filling in questionnaires will take about 10-20 minutes per week.

You will be contacted and offered a psychologist or physicians' appointment if we become concerned about your mental or physical state.

**Visit 2 at ANOVA:** After finishing treatment, you will have a follow-up visit with a physician. You will also be asked to provide urine / blood to see the concentration of the drug in the body, routine blood tests (4 tubes, approx. 16 ml) and research blood samples (2 tubes, approx. 8 ml) to examine whether the treatment has i.e. affected hormone levels.

**Visit 3 at ANOVA:** Six weeks after the end of treatment, you have a final appointment with a physician who follows up on your mood and your sexuality.

Visits 2 and 3 take about 30-60 minutes each.

If you need care after the trial, you will be guided to the type of care that best suits you. Regardless of whether you are offered treatment or not, your answers in the online survey will be an important part of the study.

### **Biobank**

Routine blood samples will be handled and destroyed according to the hospital's guidelines as in normal sampling in healthcare. The samples that are intended to be stored (5 tubes, max 30 ml) for e.g. DNA analysis and measurement of the hormone oxytocin will be stored in a biobank. The responsible biobank is Stockholms Medicinska Biobank (reg. No. 914) in accordance with the Act on Biobanks in Health Care (2002: 297), which regulates the manner

in which samples may be saved and used, and it also regulates the quality and safety of biobanks.

The samples will be stored coded, which means that the samples cannot be directly traced to you as a person. The samples and the associated identification list (code key) will be kept separate from each other, and protected from access by unauthorized persons.

Coded samples may be sent for analysis both within Sweden and the EU / USA.

**Future projects:** The blood samples will be stored pending analysis for up to 10 years, after which they will be destroyed. The samples may also be relevant for not yet unplanned research projects if you approve storage for this. A new ethical application will be made in such case, and you may be contacted again with a request for your consent. A separate request regarding future projects is provided in the enclosed consent form.

If you regret that you gave permission for your sample to be stored, you have the right to have the samples destroyed or deidentified by contacting test leader Josephine Savard, please find contact information below.

#### **Are there any risks associated with the study?**

Answering questions on private topics such as sexuality and mental health might feel uncomfortable, but these questions need to be asked so we can help you.

As for the medicine, you can experience side effects that are usually transient such as nausea, headache, vomiting and weakness. Serious side effects are uncommon with both drugs. For safety reasons, you will have to provide blood samples before and after the treatment to map, among other things, liver function. Should your samples be abnormal, we will process it according to medical practice. If you are a woman of reproductive age, you need to use safe contraception throughout the study period and submit a negative pregnancy test to be included in the study.

While blood sampling, you may experience temporary discomfort, dizziness and you may get a bruise.

During the course of the study, you could use drugs temporary such as painkillers (e.g. paracetamol) or short-term anti-anxiety medication (e.g. Atarax). Other treatment should be avoided and may lead to discontinuation from the study. This specially applies to drugs with addictive features. Ongoing drug treatment is usually suitable to continue with, but dose changes should be avoided. If in doubt, discuss with your treating physician at ANOVA.

**Warning # 1!** Should you develop symptoms such as jaundice / hepatitis (inflammation of the liver), you must immediately contact an emergency department or call 112. Symptoms of jaundice are feelings of illness, yellow staining of the skin and whites of the eyes, abdominal pain, light stools and yellow urine.

**Warning # 2!** Naltrexone counteracts the effect of opioids found in e.g. painkillers (Citodon, OxyContin /OxyNorm, Dolcontin, morphine, etc.) and in cough medicines (Cocillana-Etyfin). There are also opioids in loperamide (Dimor, Loperamide, Imodium) used to treat diarrhea. Should an emergency situation arise where you need treatment with opioids, you should immediately stop taking the study drug and inform the responsible physician about the simultaneous participation in this study.

**Warning # 3!** Should you during the course of treatment deteriorate mentally with e.g. suicidal ideation, you must contact the study psychiatrist or psychiatric emergency service at your place of residence. You will receive contact information at the start of study.

We recommend that you always carry the plastic card you are assigned at start of the study. The card has contact information to the study supervisor so that the treatment unit can obtain information about the study

### **Are there any benefits to participating in the study?**

There is a possibility that you will feel relieved to have shared your thoughts and feelings with a professional and that the drug takes the edge off the desire to commit sexual acts. It can also be an advantage to have contacted our clinic to enroll as a "regular patient" after the study period is over.

### **Data management and confidentiality**

Information about you will be registered within the framework of the study:

- Self-assessments are handled in a web-based platform that is encrypted and protected with double authentication requirements on a secure server at Karolinska Institutet.
- Other data such as interview forms and biobank samples will be handled pseudonymised, i.e. linked to you through a study code. The code key will be kept at ANOVA and protected from access by unauthorized persons.

Your answers and results will be stored in locked folders, secure digital files, encrypted databases and servers in accordance with the General Data Protection Regulation (GDPR 2016/679). Your information will not be used commercially and will be stored for a maximum of 10 years after the end of the study. All information will be handled with total confidentiality. It will not be possible to link any information to you as an individual when the results are reported.

As in ANOVA's regular care, computer-based patient records will be generated. These will not be visible outside ANOVA's record domain.

In order to verify that the collected data is handled correct, and that the procedures are performed in accordance with applicable laws and regulations, the implementation of the research study will be reviewed by an independent trial investigator. Investigators who review

the research study may be given access to decoded data and patient records together with your responsible physician and under confidentiality.

Personal data is protected and processed in accordance with the General Data Protection Regulation (GDPR 2016/679) and the Public Access to Information and Secrecy Act (2009: 400). No unauthorized person will be allowed to access the information. According to the General Data Protection Regulation, you have the right to obtain the information that is handled of you in the study free of charge and, if necessary, have any errors corrected.

If you want to take part of the information, you can contact test leader Dr Josephine Savard for more information, contact information can be found on the last page under the section Responsible. Responsible for the management of personal data is Karolinska University Hospital's Data Protection Office. The Data Protection Officer can be reached at: Karolinska University Hospital, 171 76 Solna, tel. 08-517 700 00 (switchboard operator), e-mail: [dataskyddombud.karolinska@regionstockholm.se](mailto:dataskyddombud.karolinska@regionstockholm.se). If you are dissatisfied with how your personal data is processed, you have the right to submit a complaint to the Swedish Authority for Privacy Protection, which is the supervisory authority.

### **How do I get information about the results of the study?**

The results will be published in scientific journals. Only statistical variables will be presented, and it will not be possible to identify individual participants. If you want to take part of the scientific reports, you are welcome to contact ANOVA where this study will be carried out. Information on clinical trials can be found at: [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

### **Insurance and compensation**

The regular patient insurance applies. The drugs and the visits will be free of charge.

### **Participation is voluntary**

Participation in the study is voluntary and you can withdraw your participation at any time without stating why and without it affecting your future care at ANOVA. If you want to discontinue your participation, contact the study supervisor or the test leader (contact information below). After you withdraw your participation, no new information about you will be saved. Already collected data will be preserved.

Samples: If you regret that you gave permission for us to store your samples, you have the right to have the samples discarded (this means that the samples will be destroyed or deidentified).

### **Responsible for the trial**

Responsible for the implementation of the study is ANOVA, Karolinska University Hospital. The principal researcher is Professor Jussi Jokinen ([jussi.jokinen@ki.se](mailto:jussi.jokinen@ki.se))

For questions, please contact test leader Josephine Savard, research nurse Susanne Jarlvik Alm or research assistant Pia Jaensson

Dr. Josephine Savard (Testleader)

ANOVA, Karolinska Universitetssjukhuset, 171 76 Stockholm.

E-post: [josephine.savard@regionstockholm.se](mailto:josephine.savard@regionstockholm.se), Tel +46 (0)72-5823241

Susanne Jarlvik Alm

ANOVA, Karolinska Universitetssjukhuset, 171 76 Stockholm.

E-post: [Susanne.jarlvik-alm@regionstockholm.se](mailto:Susanne.jarlvik-alm@regionstockholm.se), Tel +46 (0) 8-51772935

Pia Jaensson

ANOVA, Karolinska Universitetssjukhuset, 171 76 Stockholm.

E-post: [pia.jaensson@regionstockholm.se](mailto:pia.jaensson@regionstockholm.se), Tel +46 (0) 8-51773832

**Consent form: Drug treatment for compulsive sexuality, CeSar study.**

- I have read the written information regarding the research study and I have had the opportunity to ask questions and have them answered.
- I provide my consent to participate in the study and know that my participation is completely voluntary. I am aware that blood and urine samples need to be provided based on clinical indication. I regulate how the samples are saved (see below).
- I am aware that I can withdraw my consent and terminate my participation at any time and without explanation, as well as having collected samples discarded. The samples will then be destroyed or deidentified.
- I allow my personal information to be registered according to the information I have received and that collected data about me is stored and handled electronically by study supervisors. I allow unidentified data to be analyzed in future, unplanned studies after approval by the Ethics Review Authority.
- I allow the study supervisor or a study monitor to receive patient record information that is relevant to the current research study and that the Swedish Medical Products Agency and the corresponding supervisory authority within and outside the EU receive patient record information during any supervision.

Signature

Name in block letters

Date

-----

**Consent, research on blood samples within the framework of the study:** I give my consent that the samples I submit will be saved in the biobank and that the samples are used for research in accordance with what is described in the patient consent information.

Yes  No 

**Consent, preservation of samples for future research studies:** Your samples may be valuable for unplanned research projects (as described in this information) if you approve storage for this. In these cases, a new ethical review will take place and you may be contacted again with a request. Do you consent to that samples that remain after the completion of the Cesar study are stored for future research and may be analyzed within Sweden, the EU and the USA?

Yes  No 

Signature

Name in block letters

Date

-----

**To be completed by the investigator:** I confirm that I have provided both oral and written information about the described trial and that a copy of the patient information sheet has been handed out to the patient.

Signature

Name in block letters

Date

-----

**Supplementary Table**  
*Outcome Measures with Psychometric Properties*

Name	Psychometric properties
The Mini International Neuropsychiatric Interview (MINI)	Validated (Sheehan et al., 1998).
Hypersexual Disorder: Current Assessment Scale (HD:CAS)	Not validated Cronbach's $\alpha = 0.76$ (Savard., 2021)
The Hypersexual Behavior Inventory (HBI)	Validated test-retest reliability $r = 0.91$ ; Cronbach's $\alpha = 0.96$ (Reid et al., 2011)
Self-assessment of Sexual Interest (SSI)	Not validated (Långström, unpublished)
The Hypersexual Disorder Screening Inventory (HDSI)	Validated in Swedish inter-rater reliability $r = 0.51$ , Cronbach's $\alpha = 0.80-0.81$ (Öberg et al., 2017)
International Index of Erectile Function (IIEF)	Validated test-retest reliability $r = 0.64-0.84$ ; Cronbach's $\alpha = 0.73-0.99$ across studies. (Rosen et al., 1997; 2002)
Sexual Compulsivity Scale (SCS)	Cronbach's $\alpha = 0.89-0.92$ (Kalichman & Rompa, 1995)
The Alcohol Use Disorders Identification Test (AUDIT)	Validated in Swedish test-retest reliability $r = 0.97$ ; Cronbach's $\alpha = 0.82$ (Bergman & Kallmen, 2002)
The Drug Use Disorders Identification Test (DUDIT)	Validated in Swedish Cronbach's $\alpha = 0.80$ ; sensitivity (ranging from 0.85- 1.00) and specificity (ranging from 0.75 to 0.92) (Berman et al., 2005; Hildebrand 2015)
The Gambling Disorder Identification Test (G-DIT)	Test-retest reliability intraclass correlation coefficient = 0.93 Cronbach's $\alpha = 0.94$ (Molander et. al., 2021)
The Childhood Trauma Questionnaire – Short Form (CTQ-SF)	Validated in Swedish The inter-correlations between CTQ total scale and subscales vary between $r = 0.15-0.89$ ; Cronbach's $\alpha = 0.92$ on the total score, subscales $\alpha = 0.65-0.86$ (Bernstein & Fink, 1998; Gerdner & Allgulander 2009)



Karolinska Interpersonal Violence Scale (KIVS)	Validated in Swedish inter-rater reliability for the subscales $r = 0.91-0.95$ (Jokinen et al., 2010)
Adult ADHD Self-Report Scale (ASRS)	Validated test-retest reliability $r = 0.58-0.77$ (Kessler et al., 2007)
The Barratt Impulsiveness Scale (BIS)	Validated test-retest reliability Spearman's $\rho = 0.83$ Cronbach's $\alpha = 0.83$ (Stanford et al., 2009)
Montgomery Åsberg Depression Rating Scale – Self-rating (MADRS-S)	Validated in Swedish inter-rater reliability $r = 0.87$ ; Cronbach's $\alpha = 0.84$ (Svanborg & Åsberg 2001; Fantino, B., & Moore, N. 2009)
Hospital Anxiety and Depression Scale (HAD)	Validated in Swedish test-retest reliability $r = 0.72$ ; Cronbach's $\alpha = 0.89-0.93$ (Lisppers, J., et al. 1997)
Columbia Suicide Severity Rating Scale (C-SSRS)	Validated in Swedish C-SSRS total score, AUC = 0.65 and a cut-off of 28.5 gave a sensitivity of 69% and a specificity of 54% in predicting a non-fatal or fatal suicide attempt Cronbach's $\alpha = 0.73-0.95$ (Posner et al., 2011; Lindh et al., 2018)
UKU side effect rating scale (UKU)	Validated inter-rater reliability $r = 0.07-0.80$ (Lingjaerde et al., 1987; Lindström 2001)

Notes: Bergman, H., & Kallmen H. (2002). Alcohol use among Swedes and a psychometric evaluation of the alcohol use disorders identification test. *Alcohol and Alcoholism*, 37(3), 245–251.

<https://doi.org/10.1093/alcalc/37.3.245>

Berman, A. H., Bergman, H., Palmstierna, T., & Schlyter, F. (2005). Evaluation of the Drug Use Disorders Identification Test (DUDIT) in Criminal Justice and Detoxification Settings and in a Swedish Population Sample. *European Addiction Research*, 11(1), 22-31. <https://doi.org/10.1159/000081413>

Bernstein DP, Fink L. Childhood Trauma Questionnaire. A retrospective self-report. Manual. The Psychological Corporation, Harcourt Brace & Company, San Antonio, TX 1998

Fantino, B., & Moore, N. (2009). The self-reported Montgomery-Åsberg Depression Rating Scale is a useful evaluative tool in Major Depressive Disorder. *BMC psychiatry*, 9, 26. <https://doi.org/10.1186/1471-244X-9-26>

Gerdner, A., & Allgulander, C. (2009). Psychometric properties of the Swedish version of the Childhood Trauma Questionnaire-Short Form (CTQ-SF). *Nordic journal of psychiatry*, 63(2), 160–170. <https://doi.org/10.1080/08039480802514366>

- Hildebrand M. (2015). The Psychometric Properties of the Drug Use Disorders Identification Test (DUDIT): A Review of Recent Research. *Journal of substance abuse treatment*, 53, 52–59.  
<https://doi.org/10.1016/j.jsat.2015.01.008>
- Jokinen, J., Forslund, K., Ahnemark, E., Gustavsson, J. P., Nordström, P., & Asberg, M. (2010). Karolinska Interpersonal Violence Scale predicts suicide in suicide attempters. *The Journal of clinical psychiatry*, 71(8), 1025–1032. <https://doi.org/10.4088/JCP.09m05944blu>
- Kalichman, S. C., & Rompa, D. (1995). Sexual sensation seeking and Sexual Compulsivity Scales: reliability, validity, and predicting HIV risk behavior. *Journal of personality assessment*, 65(3), 586–601.  
[https://doi.org/10.1207/s15327752jpa6503\\_16](https://doi.org/10.1207/s15327752jpa6503_16)
- Kessler, R. C., Adler, L. A., Gruber, M. J., Sarawate, C. A., Spencer, T., & Van Brunt, D. L. (2007). Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members. *International journal of methods in psychiatric research*, 16(2), 52–65.  
<https://doi.org/10.1002/mpr.208>
- Lindh, Å.U., Waern, M., Beckman, K. et al. Short term risk of non-fatal and fatal suicidal behaviours: the predictive validity of the Columbia-Suicide Severity Rating Scale in a Swedish adult psychiatric population with a recent episode of self-harm. *BMC Psychiatry* 18, 319 (2018). <https://doi.org/10.1186/s12888-018-1883-8>
- Lindström, E., Lewander, T., Malm, U., Malt, U. F., Lublin, H., & Ahlfors, U. G. (2001). Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). *Nordic journal of psychiatry*, 55 Suppl 44, 5–69.  
<https://doi.org/10.1080/080394801317084428>
- Lingjaerde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. *Acta psychiatrica Scandinavica. Supplementum*, 334, 1–100.  
<https://doi.org/10.1111/j.1600-0447.1987.tb10566.x>
- Lisspers, J., Nygren, A., & Söderman, E. (1997). Hospital Anxiety and Depression Scale (HAD): some psychometric data for a Swedish sample. *Acta psychiatrica Scandinavica*, 96(4), 281–286.  
<https://doi.org/10.1111/j.1600-0447.1997.tb10164.x>
- Långström N. Self-assessment of Sexual Interest (SSI). Unpublished questionnaire. 2010.
- Molander, O., Wennberg, P., & Berman, A. H. (2021). The Gambling Disorders Identification Test (GDIT): Psychometric Evaluation of a New Comprehensive Measure for Gambling Disorder and Problem Gambling. *Assessment*, 10731911211046045. Advance online publication. <https://doi.org/10.1177/10731911211046045>
- Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., & Mann, J. J. (2011). The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. *The American journal of psychiatry*, 168(12), 1266–1277. <https://doi.org/10.1176/appi.ajp.2011.10111704>
- Reid, R. C., Garos, S., & Carpenter, B. N. (2011). Reliability, Validity, and Psychometric Development of the Hypersexual Behavior Inventory in an Outpatient Sample of Men. *Sexual Addiction & Compulsivity*, 18(1), 30–51. <https://doi.org/10.1080/10720162.2011.555709>

- Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997). The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. *Urology*, 49(6), 822–830. [https://doi.org/10.1016/s0090-4295\(97\)00238-0](https://doi.org/10.1016/s0090-4295(97)00238-0)
- Rosen, R. C., Cappelleri, J. C., & Gendrano, N., 3rd (2002). The International Index of Erectile Function (IIEF): a state-of-the-science review. *International journal of impotence research*, 14(4), 226–244. <https://doi.org/10.1038/sj.ijir.3900857>
- Savard, J. (2021). Compulsive sexual behavior disorder: clinical characteristics and treatment with Naltrexone (PhD dissertation, Umeå universitetet). Retrieved from <http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-186811>
- Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., & Dunbar, G. C. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *Journal of Clinical Psychiatry*, 59 Suppl 20, 22-33;quiz 34-57
- Stanford, M. S., Mathias, C. W., Dougherty, D. M., Lake, S. L., Anderson, N. E., & Patton, J. H. (2009). Fifty years of the Barratt Impulsiveness Scale: An update and review. *Personality and Individual Differences*, 47(5), 385–395. <https://doi.org/10.1016/j.paid.2009.04.008>
- Svanborg P, Asberg M. A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale (MADRS). *J Affect Disord*. 2001;64(2-3):203-16.
- Öberg, K. G., Hallberg, J., Kaldo, V., Dhejne, C., & Arver, S. (2017). Hypersexual Disorder According to the Hypersexual Disorder Screening Inventory in Help-Seeking Swedish Men and Women With Self-Identified Hypersexual Behavior. *Sexual medicine*, 5(4), e229–e236. <https://doi.org/10.1016/j.esxm.2017.08.001>